• Explore /
  • Poster
  • / A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.

A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.

Abstract Video & Slides Poster

Authors

Filip Janku

Filip Janku

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX

Filip Janku , James Strauss , Raghad Karim , Anthony J. Olszanski , Jason J. Luke , Kevin Leach , Radhakrishnan Iyer , Atif Abbas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT04096638

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3162)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3162

Abstract #

TPS3162

Poster Bd #

226

Abstract Disclosures

Similar Posters

First Author: Kevin Joseph Harrington

First Author: Ginna Laport

First Author: Judy S. Wang

First Author: Jordi Rodon Ahnert